# Park National Corp: financial statements, quarterly

PRK · NYSE · CIK 805676 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/prk.md) · [Financials](/companies/prk/financials.md) · [Filings](/companies/prk/filings.md) · [Insiders](/companies/prk/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/prk/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [153](/filings/0000805676-25-000050.md) | [158](/filings/0000805676-25-000067.md) | [170](/filings/0000805676-25-000086.md) | [165 d](/filings/0000805676-26-000017.md) | [158](/filings/0000805676-26-000039.md) | [169](/filings/0000805676-26-000061.md) | [170](/filings/0000805676-25-000086.md) | [168 d](/filings/0000805676-26-000017.md) | [189](/filings/0000805676-26-000039.md) | [212](/filings/0000805676-26-000061.md) |
| Interest expense | $m | [26.6](/filings/0000805676-23-000144.md) | [30.1 d](/filings/0000805676-24-000037.md) | [31.0](/filings/0000805676-24-000081.md) | [31.1](/filings/0000805676-24-000104.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [8.8](/filings/0000805676-24-000149.md) | [5.2 d](/filings/0000805676-26-000017.md) | [7.2](/filings/0000805676-25-000050.md) | [9.0](/filings/0000805676-25-000067.md) | [8.4](/filings/0000805676-25-000086.md) | [8.7 d](/filings/0000805676-26-000017.md) | [9.0](/filings/0000805676-26-000039.md) | [11.2](/filings/0000805676-26-000061.md) | [10.9](/filings/0000805676-25-000086.md) | [10.0 d](/filings/0000805676-26-000017.md) | [10.0](/filings/0000805676-26-000039.md) | [14.1](/filings/0000805676-26-000061.md) |
| Net income | $m | [36.9](/filings/0000805676-24-000149.md) | [24.5 d](/filings/0000805676-26-000017.md) | [35.2](/filings/0000805676-25-000050.md) | [39.4](/filings/0000805676-25-000067.md) | [38.2](/filings/0000805676-25-000086.md) | [38.6 d](/filings/0000805676-26-000017.md) | [42.2](/filings/0000805676-26-000039.md) | [48.1](/filings/0000805676-26-000061.md) | [47.2](/filings/0000805676-25-000086.md) | [42.6 d](/filings/0000805676-26-000017.md) | [41.7](/filings/0000805676-26-000039.md) | [58.8](/filings/0000805676-26-000061.md) |
| Diluted EPS | $ per share | [2.28](/filings/0000805676-24-000149.md) | not reported | [2.17](/filings/0000805676-25-000050.md) | [2.42](/filings/0000805676-25-000067.md) | [2.35](/filings/0000805676-25-000086.md) | not reported | [2.60](/filings/0000805676-26-000039.md) | [2.97](/filings/0000805676-26-000061.md) | [2.92](/filings/0000805676-25-000086.md) | not reported | [2.39](/filings/0000805676-26-000039.md) | [3.23](/filings/0000805676-26-000061.md) |
| Basic EPS | $ per share | [2.29](/filings/0000805676-24-000149.md) | not reported | [2.18](/filings/0000805676-25-000050.md) | [2.44](/filings/0000805676-25-000067.md) | [2.37](/filings/0000805676-25-000086.md) | not reported | [2.61](/filings/0000805676-26-000039.md) | [2.98](/filings/0000805676-26-000061.md) | [2.93](/filings/0000805676-25-000086.md) | not reported | [2.40](/filings/0000805676-26-000039.md) | [3.25](/filings/0000805676-26-000061.md) |

- Revenue: us-gaap:Revenues
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.2](/filings/0000805676-23-000144.md) | [0.2](/filings/0000805676-25-000014.md) | [0.3](/filings/0000805676-24-000081.md) | [0.3](/filings/0000805676-24-000104.md) | [0.2](/filings/0000805676-24-000149.md) | [0.2](/filings/0000805676-26-000017.md) | [0.2](/filings/0000805676-25-000050.md) | [0.2](/filings/0000805676-25-000067.md) | [0.2](/filings/0000805676-25-000086.md) | [0.2](/filings/0000805676-26-000061.md) | [1.0](/filings/0000805676-26-000039.md) | [0.6](/filings/0000805676-26-000061.md) |
| Total assets | $bn | [10.0](/filings/0000805676-23-000144.md) | [9.8](/filings/0000805676-26-000017.md) | [9.9](/filings/0000805676-25-000050.md) | [9.9](/filings/0000805676-25-000067.md) | [9.9](/filings/0000805676-25-000086.md) | [9.8](/filings/0000805676-26-000017.md) | [9.9](/filings/0000805676-26-000039.md) | [9.9](/filings/0000805676-26-000061.md) | [9.9](/filings/0000805676-25-000086.md) | [9.8](/filings/0000805676-26-000061.md) | [13.0](/filings/0000805676-26-000039.md) | [12.7](/filings/0000805676-26-000061.md) |
| Total liabilities | $bn | [8.9](/filings/0000805676-23-000144.md) | [8.7](/filings/0000805676-25-000014.md) | [8.7](/filings/0000805676-24-000081.md) | [8.7](/filings/0000805676-24-000104.md) | [8.7](/filings/0000805676-24-000149.md) | [8.6](/filings/0000805676-26-000017.md) | [8.6](/filings/0000805676-25-000050.md) | [8.7](/filings/0000805676-25-000067.md) | [8.5](/filings/0000805676-25-000086.md) | [8.5](/filings/0000805676-26-000061.md) | [11.3](/filings/0000805676-26-000039.md) | [10.9](/filings/0000805676-26-000061.md) |
| Long-term debt | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $bn | not reported | [0.5](/filings/0000805676-25-000014.md) | not reported | not reported | not reported | [0.3](/filings/0000805676-26-000017.md) | not reported | not reported | not reported | [0.1](/filings/0000805676-26-000017.md) | not reported | not reported |
| Short-term borrowings | $bn | [0.4](/filings/0000805676-23-000144.md) | [0.3](/filings/0000805676-25-000014.md) | [0.1](/filings/0000805676-24-000081.md) | [0.1](/filings/0000805676-24-000104.md) | [0.1](/filings/0000805676-24-000149.md) | [0.1](/filings/0000805676-26-000017.md) | [0.1](/filings/0000805676-25-000050.md) | [0.1](/filings/0000805676-25-000067.md) | [0.1](/filings/0000805676-25-000086.md) | [0.1](/filings/0000805676-26-000061.md) | [0.1](/filings/0000805676-26-000039.md) | [0.1](/filings/0000805676-26-000061.md) |
| Shareholders' equity | $bn | [1.1](/filings/0000805676-23-000144.md) | [1.1](/filings/0000805676-25-000014.md) | [1.2](/filings/0000805676-24-000081.md) | [1.2](/filings/0000805676-24-000104.md) | [1.2](/filings/0000805676-24-000149.md) | [1.2](/filings/0000805676-26-000017.md) | [1.3](/filings/0000805676-25-000050.md) | [1.3](/filings/0000805676-25-000067.md) | [1.3](/filings/0000805676-25-000086.md) | [1.4](/filings/0000805676-26-000061.md) | [1.7](/filings/0000805676-26-000039.md) | [1.7](/filings/0000805676-26-000061.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: us-gaap:DebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest, us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [39.7 d](/filings/0000805676-24-000149.md) | [53.8 d](/filings/0000805676-26-000017.md) | [35.0](/filings/0000805676-25-000050.md) | [50.9 d](/filings/0000805676-25-000067.md) | [43.8 d](/filings/0000805676-25-000086.md) | [49.2 d](/filings/0000805676-26-000017.md) | [37.7](/filings/0000805676-26-000039.md) | [49.5 d](/filings/0000805676-26-000061.md) | [52.9 d](/filings/0000805676-25-000086.md) | [58.2 d](/filings/0000805676-26-000017.md) | [30.9](/filings/0000805676-26-000039.md) | [57.2 d](/filings/0000805676-26-000061.md) |
| Capital expenditure | $m | [1.8 d](/filings/0000805676-24-000149.md) | [1.7 d](/filings/0000805676-26-000017.md) | [3.1](/filings/0000805676-25-000050.md) | [1.9 d](/filings/0000805676-25-000067.md) | [2.1 d](/filings/0000805676-25-000086.md) | [2.1 d](/filings/0000805676-26-000017.md) | [1.1](/filings/0000805676-26-000039.md) | [1.3 d](/filings/0000805676-26-000061.md) | [1.5 d](/filings/0000805676-25-000086.md) | [2.5 d](/filings/0000805676-26-000017.md) | [4.3](/filings/0000805676-26-000039.md) | [6.7 d](/filings/0000805676-26-000061.md) |
| Share repurchases | $m | [5.2 d](/filings/0000805676-24-000149.md) | [0.0 d](/filings/0000805676-26-000017.md) | [0.0](/filings/0000805676-24-000081.md) | [0.0 d](/filings/0000805676-25-000067.md) | [0.0 d](/filings/0000805676-25-000086.md) | [0.0 d](/filings/0000805676-26-000017.md) | not reported | not reported | [0.0 d](/filings/0000805676-25-000086.md) | [0.0 d](/filings/0000805676-26-000017.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [16.4](/filings/0000805676-23-000144.md) | [16.3](/filings/0000805676-24-000081.md) | [16.2](/filings/0000805676-24-000104.md) | [16.2](/filings/0000805676-24-000149.md) | [16.2](/filings/0000805676-25-000050.md) | [16.2](/filings/0000805676-25-000067.md) | [16.3](/filings/0000805676-25-000086.md) | [16.2](/filings/0000805676-26-000039.md) | [16.2](/filings/0000805676-26-000061.md) | [16.2](/filings/0000805676-25-000086.md) | [17.5](/filings/0000805676-26-000039.md) | [18.2](/filings/0000805676-26-000061.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 18,064,161 at 2026-08-06, from the cover of the [10-Q filed 2026-08-07](/filings/0000805676-26-000061.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:24 ET. No prices; not investment advice.